Sponsorship & Exhibition
Actelion Pharmaceuticals Ltd is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
We have treatments for a number of speciality care diseases with high unmet medical need including a new one for patients suffering from Mycosis Fungoides Cutaneous T-cell Lymphoma.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.
Kyowa Kirin International plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of innovative medicines and with a focus on rare diseases and therapeutic areas with high medical needs. With headquarters in Scotland, Kyowa Kirin International has business operations throughout Europe and the United States and continues to expand internationally.
Kyowa Kirin International is a wholly owned subsidiary of Kyowa Hakko Kirin Co. Ltd., a Japan-based global specialty pharmaceutical company, which for more than 9 years has been a leading research-based life sciences company with particular strength in antibody technologies for oncology, nephrology and immunology/allergy. Through its research and commercialisation of innovative medicines, the company seeks to contribute to the health and wellbeing of people around the world.
Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Our Specialty Brands segment includes branded medicines and the Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. Mallinckrodt is the only provider of integrated systems for the delivery of Extracorporeal Photopheresis (ECP). To learn more about this product, visit www.therakos.co.uk
At TAKEDA ONCOLOGY, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.
This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.
We’ve built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we’ve made great strides in our fight against cancer, we are determined to do more – to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that we are today.
We know that our mission is not a quick or simple one, but we are up for the task: we aspire to cure cancer.
Seattle Genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for cancer. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS® (brentuximab vedotin), the company’s lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs and is commercially available in 67 countries for relapsed classical Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. Seattle Genetics is also advancing vadastuximab talirine, an ADC in a phase 3 trial for acute myeloid leukemia, and in collaboration with Astellas, enfortumab vedotin, an ADC in a planned pivotal phase 2 trial for metastatic urothelial cancer. Seattle Genetics has a robust pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies. www.seattlegenetics.com
Innate Pharma is a clinical-stage biotechnology company with a focus on developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
Innate Pharma specializes in immuno-oncology, a therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells.
The Company’s aim is to become a fully-integrated biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Its innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of cancer indications as well as additional preclinical product candidates and technologies.
The Company's expertise in NK cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb and Sanofi.
Medivir AB is a Swedish clinical-stage biopharmaceutical company focused on the discovery and development of innovative pharmaceuticals for the treatment of cancer through our expertise in the design and development of protease inhibitors and nucleoside analogues. We conduct R&D in all phases of pharmaceutical development, from idea through to phase III clinical studies. Remetinostat is a new histone deacetylase (HDAC) inhibitor that Medivir is developing for the topical treatment of early-stage mycosis fungoides (MF). It has been designed to be effective in the skin but degraded rapidly in the bloodstream to avoid the adverse effects associated with systemically administered HDAC inhibitors. Following positive efficacy and safety data from our recently completed Phase II study of remetinostat gel in subjects with early-stage MF, Medivir expects to initiate a pivotal programme in the near future, and looks forward to making this potential new treatment available to patients at the earliest opportunity.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
For more than 20 years, Roche has been developing medicines that redefine treatment in haematology. Today, we are investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. In addition to approved medicines MabThera®/Rituxan® (rituximab), Gazyva®/Gazyvaro® (obinutuzumab), and Venclexta™/Venclyxto™ (venetoclax) in collaboration with AbbVie, Roche’s pipeline of investigational haematology medicines includes Tecentriq® (atezolizumab), an anti-CD79b antibody drug conjugate (polatuzumab vedotin/RG7596) and a small molecule antagonist of MDM2 (idasanutlin/RG7388). Roche’s dedication to developing novel molecules in haematology expands beyond malignancy, with the development of the investigational haemophilia A treatment emicizumab (ACE910).
4SC AG is a German clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical needs. Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life. 4SC’s core assets include resminostat,
4SC-202 and 4SC-208.
Resminostat is currently evaluated in the pivotal RESMAIN study as maintenance treatment for patients with advanced-stage mycosis fungoides or its leukemic variant Sézary Syndrome, both forms of cutaneous T-cell lymphoma (CTCL). The 150 patient study is conducted at more than 50 clinical centers in 11 European countries.
The study’s purpose is to determine whether resminostat can delay or prevent worsening of disease, compared to placebo in patients that have recently achieved disease control with systemic therapy. Patients that experience progressive disease within the placebo-arm can receive resminostat in an open study phase.